Relationship between viral load and behavioral measures of adherence to antiretroviral therapy in children living with human immunodeficiency virus in Latin America  by Duarte, Horacio A. et al.
OR
m
c
v
H
S
M
R
a
b
c
d
e
f
g
h
i
a
A
R
A
A
K
P
A
A
L
A
h
1b r a z j i n f e c t d i s . 2 0 1 5;1  9(3):263–271
w ww.elsev ier .com/ locate /b j id
The Brazilian Journal of
INFECTIOUS  DISEASES
riginal article
elationship  between  viral load  and  behavioral
easures of  adherence  to antiretroviral  therapy  in
hildren living  with  human  immunodeﬁciency
irus in Latin  America
oracio A. Duartea, Donald Robert Harrisb,∗, Katherine Tassiopoulosc, Erin Leisterd,
ilvia  Fabiana Biason de Moura Negrini e, Flávia Faleiro Ferreira f,
aria  Letícia Santos Cruzg, Jorge Pinto f, Susannah Allisonh,
ohan  Hazra i, for the NISDI PLACES Study Group1
Department of Pediatrics, University of Washington School of Medicine, Seattle, WA, USA
Westat, Rockville, MD, USA
Department of Epidemiology, Harvard School of Public Health, Boston, MA, USA
Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, MA,  USA
Department of Pediatrics, Ribeirão Preto Medical School, Universidade de São Paulo (USP), São Paulo, SP, Brazil
Faculdade de Medicina de Universidade Federal de Minais Gerais (UFMG), Belo Horizonte, MG, Brazil
Hospital Federal dos Servidores do Estado, Rio de Janeiro, RJ, Brazil
Division of AIDS Research, NIMH-NIH, Bethesda, MD, USA
Maternal and Pediatric Infectious Disease Branch, NICHD-NIH, Bethesda, MD, USA
 r  t  i  c  l  e  i  n  f  o
rticle history:
eceived 8 August 2014
ccepted 27 January 2015
vailable online 3 March 2015
eywords:
ediatric
RT
a  b  s  t  r  a  c  t
Few studies have examined antiretroviral therapy adherence in Latin American children.
Standardized behavioral measures were applied to a large cohort of human immunodeﬁ-
ciency virus-infected children in Brazil, Mexico, and Peru to assess adherence to prescribed
antiretroviral therapy doses during the three days prior to study visits, assess timing of last
missed dose, and evaluate the ability of the adherence measures to predict viral suppres-
sion. Time trends in adherence were modeled using a generalized estimating equations
approach to account for possible correlations in outcomes measured repeatedly in the
same participants. Associations of adherence with human immunodeﬁciency virus viraldherence load  were examined using linear regression. Mean enrollment age of the 380 participantsatin America was  5 years; 57.6% had undetectable’ viral load (<400 copies/mL). At enrollment, 90.8% of
participants were perfectly (100%) adherent, compared to 87.6% at the 6-month and 92.0%
at  the 12-month visit; the proportion with perfect adherence did not differ over time (p = 0.1).
Perfect adherence was associated with a higher probability of undetectable viral load at the
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12-month visit (odds ratio = 4.1, 95% conﬁdence interval: 1.8–9.1; p < 0.001), but not at enroll-
ment  or the 6-month visit (p > 0.3). Last time missed any antiretroviral therapy dose was
reported as “never” for 52.0% at enrollment, increasing to 60.7% and 65.9% at the 6- and
12-month visits, respectively (p < 0.001 for test of trend). The proportion with undetectable
viral load was higher among those who never missed a dose at enrollment and the 12-month
visit  (p ≤ 0.005), but not at the 6-month visit (p = 0.2). While antiretroviral therapy adherence
measures utilized in this study showed some association with viral load for these Latin
American children, they may not be adequate for reliably identifying non-adherence and
consequently children at risk for viral resistance. Other strategies are needed to improve
the  evaluation of adherence in this population.
© 2015 Elsevier Editora Ltda. All rights reserved.Introduction
In 2012, there were approximately 56,000 children under
15 years of age living with HIV in Latin America and the
Caribbean.1 With increased availability of antiretroviral ther-
apy (ART), there has been a signiﬁcant decrease in the
morbidity and mortality of perinatally infected children.2,3
Success in achieving good outcomes relies on high levels of
ART adherence to maximize clinical effectiveness and limit
potential for development of drug resistance.4
Few studies from Latin America have estimated ART adher-
ence levels in children or evaluated the validity of methods
used to measure adherence.5 Among the various methods
used in resource-limited settings, behavioral measures of
adherence, including self- and caregiver-report, are the most
common.6 Behavioral methods are attractive because they are
practical and inexpensive. However, few studies in resource-
limited settings have attempted to validate their accuracy by
comparing them with other adherence measurement tools,
and those that have produced mixed results.7–12 In this sub-
study of the NICHD (Eunice Kennedy Shriver National Institute
of Child Health and Human Development) International Site
Development Initiative (NISDI) PLACES (Pediatric Latin Ameri-
can Countries Epidemiologic Study) protocol, we assessed ART
adherence levels and evaluated the ability of the adherence
measures to predict viral suppression among children living
with HIV in Latin America.
Materials  and  methods
Participants
Participants were children living with HIV and their care-
givers that enrolled in PLACES, a prospective cohort study that
enrolled perinatally HIV-infected children less than 6 years of
age at the time of enrollment at 14 clinical sites (12 in Brazil,
1 each in Peru and Mexico). The protocol was approved by
the ethical review boards of each clinical site, the sponsor-
ing institution (NICHD), the data management and statistical
center (Westat), and the Brazilian National Ethics Committee
(CONEP). Informed consent was obtained from the parents or
guardians prior to enrollment.A description of the earlier version of the protocol and
the cohort, including the site selection process, has been
published elsewhere.13 In brief, demographic, laboratory, and
clinical data were collected at enrollment and every 6 months,
including HIV-1 RNA viral load (VL), CD4 measures, CDC clas-
siﬁcation, and antiretroviral medication adherence.
Adherence  measures
ART adherence was assessed through a structured question-
naire developed for use by the U.S. National Institute of Allergy
and Infectious Diseases (NIAID) as part of standard practice
in PACTG (Pediatric AIDS Clinical Trials Group) studies.14
The potential for social desirability bias with self-/caregiver-
reported adherence was considered in the design of the PACTG
instrument and the instructions for its administration, which
were followed in our study. These instructions emphasize
that the accuracy of self-report is very good if the attitude of
the interviewer is non-judgmental and supportive. To set the
proper tone, the adherence form includes introductory state-
ments acknowledging how difﬁcult adherence can be that
were read verbatim. The participant/caregiver was asked to
identify the ARV medications and number of doses (not num-
ber of pills) prescribed each day. The participant/caregiver
was prompted regarding any omitted medications if all of
the prescribed ARV medications identiﬁed during medical
chart review by the interviewer were not reported. Inter-
viewees were then asked to report the number of missed
doses for each ARV medication for each of the previous three
days. The interviewer asked about speciﬁc problems that
may have been encountered in giving or taking medications.
Instructions printed on the form stressed that any interac-
tion occurring after the form was completed in response
to non-adherence was critically important, noting that the
attitude of the interviewer in response to non-adherence,
the manner in which adherence would be promoted, and
the nature of any behavioral counseling offered would
absolutely inﬂuence the validity of subsequent self-report
data.
The interview was administered in Spanish or Portuguese
by a member of the clinical care or research team to the
person with primary responsibility for medication administra-
tion. Certiﬁed translations were performed by an independent
company using language experts (English and the relevant
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anguage for translation) that had a scientiﬁc background and
ere well versed in medical terminology.
ART adherence was derived based on the total number of
oses missed during the three-day period prior to a study visit
nd the total number of expected doses for all of the ARVs
ncluded in the participant’s treatment regimen at the time of
he visit. The measure was expressed in the form of a con-
inuous measure of percent adherence calculated as shown
elow; adherence was also examined on the basis of a binary
ndicator of perfect (100%) adherence.
ercent adherence =  100 ∗
[
1 −
(∑
doses missed in time period/
∑
expected doses in time period
)]
Participants/caregivers were also asked to recall when
hey/the child last missed a dose of any ARV medication;
esponse options included never, during the previous two
eeks, during the last month, over a month ago or don’t
emember. This measure was dichotomized for purposes of
nalysis (never vs. ever).
tatistical  analyses
imple descriptive statistics (mean, standard deviation,
edian, frequency count, percentage) were used to describe
haracteristics of the study population and adherence meas-
res. Trends in adherence and VL across the three study
isits (enrollment and 6 and 12 months post-enrollment)
ere modeled using a generalized estimating equations (GEE)
pproach to account for possible correlations in outcomes
hen measured repeatedly in the same participants. The
ssociation of behavioral measures of ART adherence with
L, a standard biomarker of adherence, was examined using
inear regression modeling and Fisher’s exact test. VL values
elow the limit of detection were set to one-half of the lower
imit of detection for the assay for purposes of analysis (i.e., VL
400 set to 200), while those reported as greater than a speci-
ed value were set to the associated value (i.e., VL >500,000 set
o 500,000). All analyses were performed using the SAS soft-
are system, version 9.2, with an alpha level of 0.05 used in
ssessing statistical signiﬁcance using two-tailed tests.
esults
mong the 500 PLACES study participants, there were 387
ho  were currently prescribed HIV medications at the time
f enrollment and therefore eligible for inclusion in the anal-
ses; the 113 participants not currently prescribed ART at
nrollment were excluded from the analysis. An additional
even participants that had assumed responsibility for their
wn drug regimen and completed the adherence interview
hemselves were excluded from the analysis to create a more
omogenous population for investigation. Characteristics of
he 380 participants included in the analyses are described
n Table 1. The mean age of the participants was 5.0, ran-
ing from <1 to 11 years, and most were enrolled in Brazil
72.9%). The primary caregiver was a biological parent for5;1 9(3):263–271 265
81.1% of children. A primary caregiver had sole responsibility
for administering ARTs for 85.4% of children, while only 0.8%
of study participants assumed sole responsibility themselves.
The mean (±standard deviation) nadir CD4 count at enroll-
ment was 925 ± 589 cells/mm3; mean peak log10 viral load
(copies/mL) at or before enrollment was 5.4 ± 1.2. Ninety-ﬁve
percent of the children were on combination ART. Eighty-four
percent of study participants had received two or more  regi-
mens by the time of study enrollment; the number of ART
regimens received considered changes from one drug class to
another, but not changes within class. The mean duration of
ARV use at enrollment was 47.4 ± 35.7 months.
With few exceptions, the expected number of doses per
24-h period abstracted by the study nurse from the medical
record equaled the number of doses reported by the primary
caregiver for the same period for all study visits (data not
shown). Mean (median) percent adherence over the past three
days was 98.4% (100%) at enrollment, decreasing modestly to
96.6% (100%) and 96.5% (100%) at the 6- and 12-month visits,
respectively (Table 2); 5% or less of study participants did not
have adherence data collected/recorded at each study visit.
Despite the small magnitude of these differences, a model ﬁt
to the data showed that percent adherence varied signiﬁcantly
over time (p = 0.006); in pairwise comparisons, percent adher-
ence differed between enrollment and the 6- and 12-month
visits (p < 0.04), but not between the 6- and 12-month visits
(p = 1.0). At enrollment, 90.8% of participants were perfectly
(100%) adherent, compared to 87.6% at the 6-month and 92.0%
at the 12-month visit; the proportion with perfect adherence
did not differ over time (p = 0.1). When doses were missed, they
were typically missed only for a subset of the drugs included
within the prescribed regimen, they were usually missed for
only one of the three days targeted by the adherence ques-
tionnaire, and the ART doses that were missed tended to
represent only a portion of the expected number of doses
rather than all doses of a speciﬁc medication for a given day
(data not shown).
When asked about the last time a dose of any prescribed
ART was missed, a large proportion of participants at each
visit never missed a dose (52.0% at enrollment, 60.7% at 6
months, 65.9% at 12 months) (Table 2); this measure of adher-
ence varied signiﬁcantly over time (p < 0.001). The probability
of never missing a dose was higher at the 6- and 12-month
visits, compared to the enrollment visit (odds ratio (OR) = 1.4
[95% conﬁdence interval (CI): 1.1–1.8; p = 0.003] and 1.8 [95% CI:
1.4–2.3; p < 0.001], respectively), but did not differ between the
6- and 12-month visits (p = 0.07).
Mean (±SD) log10 VL varied over time (p < 0.001) (Table 2),
with pairwise comparisons indicating that VL at the 6-
and 12-month visits was signiﬁcantly lower than at enroll-
ment (p = 0.01 and <0.001, respectively), while the difference
between the 6- and 12-month visits was of marginal
signiﬁcance (p = 0.052). Similarly, the occurrence of VL
<400 copies/mL varied signiﬁcantly over time (p = 0.005), with
57.6% at enrollment, compared to 63.4% at the 6-month and
65.0% at the 12-month visits. The probability of having a VL
measure <400 copies/mL at 6 (OR = 1.3, 95% CI: 1.1–1.5; p = 0.01)
and 12 months (OR = 1.4, 95% CI: 1.1–1.7; p = 0.002) was higher
than at the enrollment visit, but did not differ between the 6-
and 12-month visits (p = 0.4).
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Table 1 – Characteristics of study population (N = 380).
Characteristic
Child’s age at enrollment (completed years): mean (SD) 5.0 (3.1)
Child’s gender: n (%) female 190 (50.0)
Race: n (%)
Black of African heritage or African American 74 (19.5)
Mestizo 161 (42.4)
Mulato 1 (0.3)
White 144 (37.9)
Country: n (%)
Brazil 277 (72.9)
Mexico 63 (16.6)
Peru 40 (10.5)
Primary caregiver: n (%)
Both biological parents 120 (31.6)
Biological mother only 164 (43.2)
Biological father only 24 (6.3)
Other relative 34 (8.9)
Adoptive parents 17 (4.5)
Foster parents 5 (1.3)
Foster care manager 16 (4.2)
Person responsible for administering medications: n (%)
Primary caregiver solely responsible 323 (85.4)
Study participant solely responsible 3 (0.8)
Study participant and caregiver jointly responsible 13 (3.4)
Other 39 (10.3)
Missing 2
Education level of primary caregiver (years completed): mean (SD) 7.8  (4.0)
Nadir CD4 count (cells/mm3) at enrollment: mean (SD) 925 (589)
Nadir CD4 percent at enrollment: mean (SD) 25.3 (10.3)
Peak log10 viral load (copies/mL) at or before enrollment: mean (SD) 5.4 (1.2)
CDC disease classiﬁcation: n (%)
Category N 18 (4.7)
Category A 85 (22.4)
Category B 113 (29.7)
Category C 164 (43.2)
CDC immunologic category: n (%)
No evidence of suppression 66 (17.4)
Evidence of moderate suppression 145 (38.3)
Severe suppression 168 (44.3)
Missing 1
WHO disease classiﬁcation: n (%)
Stage 1 49 (12.9)
Stage 2 123 (32.4)
Stage 3 106 (27.9)
Stage 4 102 (26.8)
WHO immunologic category: n (%)
None or not signiﬁcant 74 (19.8)
Mild immune suppression 58 (15.5)
Advanced 53 (14.2)
Severe (AIDS) 189 (50.5)
Missing 6
Number of prior ART regimens by time of enrollment: n (%)
0 8 (2.1)
1 52 (13.7)
2 77 (20.3)
3+ 243 (63.9)
Duration of ART exposure by time of enrollment: (months)
Mean (SD) 47.4 (35.7)
Median 40.4
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Table 2 – Description of behavioral measures of ART adherence and viral load measures by study visit (n = 380).
Study visit p-value*
Enrollment 6-months post
enrollment
12-months post
enrollment
ART adherence measures
Percent adherence over the past 3 days
Mean (SD) 98.4  (5.7) 96.6 (12.3) 96.5 (15.8) 0.006
Median 100 100 100
Data not available** 9 17 19
Perfect (100%) adherence: n (%) yes 337 (90.8) 318 (87.6) 332 (92.0) 0.1
Data not available** 9 17 19
Last time missed dose of any ART
prescribed: n (%) never (vs. ever)
197  (52.0) 224 (60.7) 240 (65.9) <0.001
Data not available** 1 11 16
Viral load measures
Log10 VL (copies/mL): Mean (SD) 2.85 (1.33) 2.71 (1.28) 2.61 (1.26) <0.001
Data not available** 5 6 9
VL <400 copies/mL: n (%) 216 (57.6) 237 (63.4) 241 (65.0) 0.005
Data not available** 5 6 9
p-values <0.05 are bolded.
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∗∗ Data not collected or recorded during study visit.
Regression modeling indicated that percent adherence was
nversely, but not signiﬁcantly, associated with log10 VL at
he enrollment or 6-month visit (p > 0.1) (data not shown).
t 12 months, a 5-percent increase in adherence was asso-
iated with a small (−0.09) decline in log10 VL (p < 0.001); the
odel indicated that only 5.7% of the variation in VL could be
xplained by variability in percent adherence.
Perfect adherence was associated with VL <400 copies/mL
nly at the 12-month study visit (p < 0.001) (Table 3); a
igher proportion of those with perfect adherence had VL
400 copies/mL (68.3%) than among those with less than per-
ect adherence (34.5%). The probability of having a VL measure
400 copies/mL at 12 months was more  than four times higher
mong those with perfect adherence than those with less than
erfect adherence (OR = 4.1, 95% CI: 1.8–9.1).
The proportion of participants with VL <400 copies/mL at
nrollment was higher among those who reported never miss-
ng any medication dose vs. those that had missed a dose
64.8% vs. 50.3%, p = 0.005) (Table 3). Likewise, at the 6-month
isit, subjects who  never missed a dose were more  likely to
ave viral load <400 copies/mL (66.4%) than those who did
iss a dose (59.7%), but this difference was not statistically
igniﬁcant (p = 0.2). At the 12-month visit, the difference was
gain statistically signiﬁcant (p < 0.001), as the proportion with
L <400 copies/mL at 12 months was higher among those who
eported never missing an ART medication dose (72.2%) com-
ared to those who  had (52.0%).
iscussionhe mean caregiver reported ART adherence was above 96%
t each targeted study visit for this cohort of young chil-
ren living with HIV in Latin America. The majority of studyg.
participants did not report missing any doses of their pre-
scribed ART regimen in the past three days. Those that did
report missing doses typically missed only some of the doses
for some of the drugs included within their prescribed regi-
men, and usually missed doses for only one of the three days
assessed.
Despite their widespread use, research is mixed on the util-
ity of self-report adherence measures for children living with
HIV. Some previous studies from both developed countries
and resource-limited settings have failed to show an asso-
ciation between behavioral measures of ART adherence and
VL in HIV-infected pediatric patients, while other studies
have found strong associations between VL and behavioral
adherence measures.7,12,15–18 The validity of self-reported
adherence has been examined in a systematic review of
77 studies19 and in a meta-analysis of 65 studies.20 These
reviews concluded that self-report correlates with objective
adherence measures including electronic monitoring systems
and HIV health indicators, such as VL. Several guidelines
have recommended the use of self-report for adherence
measurement21,22 since it offers the advantages of low cost,
minimal patient and clinician burden, ﬂexible design to suit
individual language abilities, and ease of data collection,
which are especially useful in resource-limited settings.19,23
Aside from these practical considerations, self-report can
facilitate discussion between patients and providers con-
cerning reasons for non-adherence. As previously noted, the
adherence instrument used in our study has been validated for
use as part of standard practice in PACTG therapy studies.14,24
Beyond its extensive application in U.S. studies, this ques-
tionnaire or slight modiﬁcations of such have been adopted
for use in many  countries, including Brazil25; Cambodia26,27;
Nepal28; South Africa7; Thailand26,29,30; and Uganda,9 to name
a few.
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Table 3 – Association of perfect adherence and long-term behavioral adherence measure with viral load <400 copies/mL
at enrollment and the 6- and 12-month post enrollment visits.
Study visit N Viral load <400 copies/mL
n (%)
p-value*
Perfect (100%) adherence (vs. less than perfect adherence)
Enrollment Perfect adherence 332 195 (58.7) 0.6
Less than perfect adherence 34 18 (52.9)
6-months post enrollment Perfect  adherence 317 206 (65.0) 0.3
Less than perfect adherence 44 25 (56.8)
12-months post enrollment Perfect adherence 328 224 (68.3) <0.001
Less than perfect adherence 29 10 (34.5)
Last time missed a dose of any ART prescribed (never vs. ever)
Enrollment Never missed dose 193 125 (64.8) 0.005
Ever missed dose 181 91 (50.3)
6-months post enrollment Never  missed dose 223 148 (66.4) 0.2
Ever missed dose 144 86 (59.7)
12-months post enrollment Never missed dose 237 171 (72.2) <0.001
Ever missed dose 123 64 (52.0)p-values <0.05 are bolded.
∗ p-values obtained from Fisher’s exact test.
Although neither of our adherence measures were con-
sistently, signiﬁcantly associated with VL <400 copies/mL,
consistent trends were observed between VL and perfect
adherence, and even more  so for the timing of last missed
dose of any medication, supporting the use of longer periods
of recall for better identifying those with adherence difﬁcul-
ties. One US-based study found a correlation between no doses
missed in the previous month and VL, while another study
found that, although caregiver 3-day recall and reporting of
doses missed during the previous six months were not asso-
ciated with VL, recall of doses taken over the last 6 months
was signiﬁcantly related to VL.17,31 A meta-analysis exam-
ining ART adherence in HIV-infected children, adolescents
and young adults that included studies conducted in the US,
Africa, Europe, Thailand, Haiti and Brazil, found that the two
most frequently assessed time periods for those using self-
/caregiver-report were the past month, followed by the past
two to four days.32
A major challenge associated with the use of self-report
that may have inﬂuenced our results is a tendency for over-
estimation of adherence by participants/caregivers, as this
method is susceptible to recall bias and social desirability
bias, whereby respondents tend to provide answers to ques-
tions that will be viewed favorably by the interviewer.33 A
Ugandan study reported adherence to ART of 95% or greater
for 89% of children between 2 and 18 years of age using
3-day caregiver/self-report, compared to only 72% for home-
based unannounced pill counts, an objective measure of
adherence.9 In Cape Town, South Africa, mean adherence
according to caregiver-reported visual analog scale (VAS) was
98.6%, while it was only 79.6% according to MEMS (Medication
Event Monitoring System).8 While it is true that self-report
by children and caregivers may overestimate adherence by
about 10–20% compared to electronic monitoring methods,34
other commonly used measures of medication adherence,
such as MEMS  caps, pill counts, pharmacy records, and bloodconcentrations, are also subject to limitations that can lead
to biased adherence estimates. While unlikely to have elim-
inated social desirability bias altogether, use of the PACTG
adherence questionnaire, with its standardized scripts and
method of administration, should have helped in reducing its
extent.
Although the NISDI adherence questionnaire had previ-
ously been used in developed countries for Spanish speaking
individuals, its cultural validity was not tested prior to its
use in this Latin American population. This lack of cultural
adaptation has been observed for several other pediatric ART
adherence questionnaires used in low- and middle-income
countries, and may have played a role in limiting the asso-
ciation between reported adherence and VL in this study.6
A major challenge in evaluating the validity of behav-
ioral measures of adherence is the lack of a gold standard
for measuring ART adherence in children. Although we
assessed the NISDI adherence questionnaire against VL, this
is not a perfect benchmark for evaluating how accurately a
particular approach measures adherence. Indeed, the rela-
tionship between adherence and VL is complex and can
be affected by factors other than adherence. Among adults,
the risk of virologic failure (≥50 copies/mL) was shown to
decrease with longer duration of continuous viral suppression,
even with adherence of 50–74%.35 In adults receiving NNRTI
(Non-nucleoside Reverse Transciptase Inhibitor)-containing
regimens, it has been reported that viral suppression can
be achieved with adherence levels as low as 54%.36 A study
using 3-day report found that the percentage of children with
undetectable VL (<400 copies/mL) was signiﬁcantly higher
among fully adherent than non-adherent children (50% vs.
27%, p < 0.001).24 However, many  fully adherent children had
detectable VL, possibly due to previous sub-optimal treatment
that led to drug resistance and sub-optimal suppression of
viral replication, and some non-adherent children had unde-
tectable VL. Recognizing that full adherence would only be
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xpected to lead to undetectable VL for participants receiv-
ng effective therapy, the authors examined the relationship of
dherence to VL, restricted to those receiving HAART (Highly
ctive Antiretroviral Therapy) with or without a PI (Protease
nhibitor). The authors found a signiﬁcant association within
his subgroup (p > 0.001), but not among those not receiving
on-HAART combination regimens or among those receiving
3 NRTIs (Nucleoside Reverse Transcriptase Inhibitor).
Achieving correct dosing is particularly challenging in pedi-
tric patients due to limited pediatric ﬁxed dose formulations
nd differences in the way drugs are metabolized in children,
ossibly leading to incorrect dosing.37 Consequently a child
ould have a high level of adherence without viral suppres-
ion if his/her regimen is under-dosed. Although a participant
ight be adherent, their medications may not be taken as
irected with respect to the timing of doses and timing of food
onsumption, which could reduce medication effectiveness.24
hildren who  have developed resistance would also not be
xpected to achieve viral suppression despite high levels of
dherence; high prevalence of viral resistance has been iden-
iﬁed in several cohorts of perinatally infected children.38–40
inally, children have greater difﬁculty in achieving optimal
iral suppression than adults, which has been attributed to
igher baseline viral load and differences in viral dynamics.41
In conclusion, the current ART adherence questionnaire
tilized for NISDI pediatric patients demonstrated some asso-
iation with viral load, but may not be adequate for reliably
dentifying non-adherence and consequently children at risk
or viral resistance. Future studies using behavioral measures
f adherence in Latin American populations should consider
sing longer periods of recall; better framing caregiver and
elf-report questions; and computer administration of the
uestionnaires (as opposed to face-to-face interviews) in an
ffort to reduce social desirability; and working to ensure that
he questions are culturally acceptable. The use of more  objec-
ive measures of adherence in addition to viral load, such as
ill counts or pharmacy records, should be considered when
ossible, as well as combining objective measures with self-
eport measures.
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